水素富化水の筋ジストロフィー・炎症性筋疾患・ミトコンドリア筋疾患に対するオープンラベル試験および二重盲検プラセボ対照クロスオーバー試験
An open-label trial administered 1.0 liter per day of hydrogen-enriched water for 12 weeks to five patients with progressive muscular dystrophy (PMD), four with polymyositis/dermatomyositis (PM/DM), and five with mitochondrial myopathies (MM). Significant changes were found in lactate-to-pyruvate ratios in PMD and MM, fasting blood glucose in PMD, serum MMP3 in PM/DM, and serum triglycerides in PM/DM. A subsequent randomized, double-blind, placebo-controlled crossover trial using 0.5 liter per day for 8 weeks in 10 DM and 12 MM patients revealed a statistically significant reduction in lactate levels in MM, with favorable but non-significant trends in lactate-to-pyruvate ratios and MMP3. One insulin-dependent MELAS patient experienced hypoglycemic episodes that resolved after insulin dose reduction. The authors suggest that the attenuated effects in the double-blind phase may reflect a dose-response or threshold relationship.
H2 is proposed to selectively scavenge hydroxyl radicals and peroxynitrite while also modulating intracellular signaling, thereby reducing mitochondrial dysfunction and inflammatory processes in affected muscle tissue.
Hydrogen-rich water is a low-risk delivery route, but the achievable systemic hydrogen dose is bounded. For clinical applications, inhalation is the most efficient route; inhalation, however, carries explosion risk, and concentration matters (empirical LFL of 10% applies to inhalation environments; high-concentration devices are documented in the Consumer Affairs Agency accident database and are not recommended).
See also:
https://h2-papers.org/en/papers/22146674